Le Lézard
Classified in: Business
Subject: ECO

T. Rowe Price Mid-Year Market Outlook: Generally Favorable Economic Environment Seen, Though Volatile Conditions From First Half Of Year Likely To Persist


BALTIMORE, June 25, 2018 /PRNewswire/ --

NEWS  

After a solid year with relatively little volatility in many global financial markets in 2017, volatility returned in the first half of 2018. High valuations across most global asset classes and a range of economic and policy risks ? including the threat of trade protectionism ? create the potential for volatility to persist moving into the second half of 2018. Such volatility could produce potentially attractive buying opportunities for long-term investors.

The global economic expansion appears to be intact, despite slowing momentum in Europe and Japan, and some developed markets are clearly in an interest rate tightening regime. China has been able to sustain its growth, which is fueling expansion in other emerging markets, although currency weakness could create risks for countries with large budget deficits. The growth outlook is most robust in the U.S., where confidence remains high on the heels of last year's tax cut legislation for individuals and corporations.

KEY MID-YEAR OBSERVATIONS

QUOTES

Rob Sharps, Head of Investments and Group Chief Investment Officer
"The key question going forward will be whether the global economic expansion and the bull market in risk assets have entered a late stage, a phase typically marked by inflationary pressures, rising interest rates, and deteriorating profit margins.  Some signs point in that direction but it would be a mistake to assume that because the current expansion has been long, it must be nearing its end.  The recovery has been long, but it has also been slow.  It may be that markets are in a mid-cycle pause as central banks around the world recalibrate monetary policy for a more sustainable expansion."

"The fundamental environment is great, but it's not getting any better.  Risks are rising, and investors should consider positioning their portfolios a little more conservatively at the margin, but not overdo it.  We're not necessarily at the end of a bull cycle, but if you take a multi-year view, you should probably expect lower returns going forward than what we've experienced over the last couple of years."

Justin Thomson, Portfolio Manager and Chief Investment Officer of Equity
"We're seeing a similar pattern all over the world, emerging markets included, where markets are highly bifurcated between companies that can demonstrate structural growth and companies that are structurally challenged.  And the blend that comes out in the aggregate is perhaps less meaningful than it once was.  Europe's strong earnings momentum from 2017 will be difficult to replicate in 2018, in part because the technology sector has been the catalyst for earnings growth and it has a smaller weight in the major European indexes relative to the U.S.  Still, underlying trends appear positive."

Mark Vaselkiv, Portfolio Manager and Chief Investment Officer of Fixed Income
"We could have some interesting dynamics going forward if the world starts to lose a little bit of confidence in our geopolitical situation, particularly our trillion dollar deficits.  The potential for financial contagion among emerging markets can't be dismissed, particularly among countries that have made less progress in curbing chronic deficits.  It's one of the key trends we will be watching over the next six months.  And since all emerging countries economically revolve around China, a meaningful trade conflict between the U.S. and China would have serious implications."

ABOUT T. ROWE PRICE

Founded in 1937, Baltimore-based T. Rowe Price Group, Inc. is a global investment management organization with $1.04 trillion in assets under management as of May 31, 2018.  The organization provides a broad array of mutual funds, subadvisory services, and separate account management for individual and institutional investors, retirement plans, and financial intermediaries.  The company also offers sophisticated investment planning and guidance tools.  T. Rowe Price's disciplined, risk-aware investment approach focuses on diversification, style consistency, and fundamental research.  For more information, visit troweprice.com or our Twitter, YouTube, LinkedIn, and Facebook sites.

Information and opinions, including forecasts and forward-looking statements, are derived from proprietary and non-proprietary sources deemed to be reliable; the accuracy of those sources is not guaranteed, and there can be no assurance that actual results will not differ materially from expectations. This does not constitute a distribution, an offer, an invitation, a recommendation, or a solicitation to sell or buy any securities in any jurisdiction. All investments are subject to market risk, including the possible loss of principal.

SOURCE T. Rowe Price Group, Inc.


These press releases may also interest you

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 20:39
Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New...

at 20:15
The partnership was unveiled internally at the Franchisor's annual convention in Las Vegas, NV in December 2023, eliciting...

at 19:35
Regenx Tech Corp., (the "Company" or "Regenx") is providing this bi-weekly update on the status of the application to the Alberta Securities Commission for a management cease trade order, under National Policy 12-203 -?? Management Cease Trade...

at 19:14
Kadestone Capital Corp. ("Kadestone" or the "Company") , a vertically integrated property company today announced its financial results for the year ended December 31, 2023....

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...



News published on and distributed by: